Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $11.00 USD
Change Today -1.02 / -8.49%
Volume 430.7K
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

calithera biosciences inc (CALA) Snapshot

Open
$11.82
Previous Close
$12.02
Day High
$12.27
Day Low
$10.95
52 Week High
12/15/14 - $33.48
52 Week Low
10/10/14 - $6.51
Market Cap
197.4M
Average Volume 10 Days
497.4K
EPS TTM
--
Shares Outstanding
17.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CALITHERA BIOSCIENCES INC (CALA)

Related News

No related news articles were found.

calithera biosciences inc (CALA) Related Businessweek News

No Related Businessweek News Found

calithera biosciences inc (CALA) Details

Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate includes CB-839, an inhibitor of glutaminase, which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience’s portfolio of arginase inhibitors for use in human healthcare. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California.

37 Employees
Last Reported Date: 03/27/15
Founded in 2010

calithera biosciences inc (CALA) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $560.0K
Senior Vice President of Development
Total Annual Compensation: $405.0K
Senior Vice President of Drug Discovery
Total Annual Compensation: $405.0K
Senior Vice President of Research
Total Annual Compensation: $364.1K
Compensation as of Fiscal Year 2014.

calithera biosciences inc (CALA) Key Developments

Calithera Biosciences, Inc. Reports Initial Phase I Data for Cb-839 in Patients with Acute Leukemias

Calithera Biosciences, Inc. announced that data from it’s lead, first-in-class program CB-839 will be presented at the 20thCongress of the European Hematology Association (EHA) June 11, 2015 to June 20, 15, 2015, in Vienna, Austria. These preliminary data demonstrate the clinical activity, tolerability and unique mechanism of action of CB-839 in patients with acute leukemia. As of March 1, 2015, fifteen patients with acute myeloid leukemia (AML) had been treated in Calithera's Phase I clinical trial of CB-839 in patients with relapsed or refractory acute leukemias.  Oral CB-839 was administered continuously in 21-day treatment cycles from 100 mg to 1,000 mg three times daily. There were no dose limiting toxicities identified.  Treatment-related adverse events of any grade that occurred in >10% of patients were limited to increases in transaminases (4 patients) and bilirubin (2 patients).  There were no Grade =3 adverse events that were considered treatment-related in >10% of patients. Stable disease for 4-10 cycles was observed in 5 (33%) of 15 efficacy-evaluable AML patients across all dose levels, with patients remaining on study for an average of 134 days (>6 cycles). One of these patients achieved a complete response in the bone marrow with incomplete recovery of peripheral counts (CRi) after 6 cycles of dosing.  All of the patients with stable disease or better were over 65 years of age, and not eligible for high dose therapy.

Calithera Biosciences, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2015

Calithera Biosciences, Inc. reported unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, loss from operations was $7,867,000 against $4,150,000 a year ago. Net loss was $7,858,000 against $4,149,000 a year ago.

Calithera Biosciences, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-12-2015 08:00 AM

Calithera Biosciences, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-12-2015 08:00 AM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Christopher J. Molineaux, Senior Vice President of Development, Susan M. Molineaux, Co-Founder, Chief Executive Officer, President and Director, William D. Waddill, Chief Financial Officer, Senior Vice President, Treasurer and Secretary.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CALA:US $11.00 USD -1.02

CALA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CALA.
View Industry Companies
 

Industry Analysis

CALA

Industry Average

Valuation CALA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CALITHERA BIOSCIENCES INC, please visit www.calithera.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.